Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma
Pranabashis Haldar Respiratory Biomedical Research Unit, Glenfield Hospital, University of Leicester, Leicester, UK Abstract: Mepolizumab (Nucala®) is an effective and specific anti-eosinophil molecular therapy that has recently been approved as add-on therapy for the management of severe eo...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2017-06-01
|
| Series: | Biologics : Targets & Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/patient-profiles-and-clinical-utility-of-mepolizumab-in-severe-eosinop-peer-reviewed-article-BTT |